Cardiometabolic Consequences of the Loss of Ovarian Function

NCT06264882 | Recruiting Phase 4 DMC FDA Drug

• 2 other identifiers: 23-1518U54AG062319
• Study Type: interventional
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

The menopause transition is associated with a decrease in artery health and an increased risk for weight gain in storing fat in the stomach area which may increase the risk for heart disease. The purpose of this research is to study how the decrease in estrogen at menopause changes artery health and fat gain, and risk of disease in women as they age. The first aim in this study will determine whether short term and long term low estrogen levels in premenopausal women decreases artery function and whether this is related to an increase in fat in the stomach area. The second aim will determine whether the changes in artery health and body fat are related to changes in a pathway that breaks down an important amino acid called tryptophan. This pathway is thought to play a role in regulating the aging process. Therefore, the investigators will determine whether the decrease in artery health and the increase in body fat in the stomach region with low estrogen is related to changes in this pathway in the blood, in vascular cells and fat tissue. Because estrogen levels fluctuate in premenopausal women, the investigators will use an approach (intervention) that controls estrogen levels to address these aims. The investigators will use a medication that is typically used to treat endometriosis or uterine fibroids to lower estrogen levels and an estrogen patch to increase estrogen in some women. Some women will receive a patch that has no estrogen (called a placebo patch). The intervention period will be 20 weeks. The study will provide us with new knowledge on how low estrogen with menopause affects artery health and fat gain estrogen.

Conditions

Menopause; Estrogen Deficiency; Aging; Adiposity

Keywords

Vascular biology; Women's health; Women

Outcome Measures

Primary Outcomes (1)

• Brachial artery flow mediated dilation (FMD)

  Ultrasound measurements of brachial artery FMD will be performed in the morning under fasted conditions, and analyzed (Vascular Analysis Tools 5.5.1) according to guidelines. Baseline FMD will be assessed during early follicular phase of menstrual cycle. Blood pressure will be measured prior to the FMD. To confirm endothelial-specific effects of the intervention, the investigators will also measure endothelium-independent dilation as brachial artery dilation to sublingual nitroglycerine (0.4 mg). All ultrasound images will be coded by number and blinded to group assignment.

  Baseline and at 2 and 20 weeks

Secondary Outcomes (1)

• Visceral fat area (VFA)

  Baseline and at 20 weeks

Other Outcomes (20)

• Subcutaneous fat area

  Baseline and at 20 weeks

• Tryptophan-Kynurenine metabolites

  Baseline and at 2 and 20 weeks

• Body composition - mass

  Baseline and at 20 weeks

Study Arms (2)

Degarelix plus transdermal placebo

EXPERIMENTAL

At baseline \& 10 weeks: 80-mg subcutaneous injection of degarelix acetate plus Placebo transdermal patch (applied twice per week)

Drug: Degarelix; Drug: Transdermal Placebo Patch

Degarelix plus transdermal estradiol

EXPERIMENTAL

At baseline \& 10 weeks: 80-mg subcutaneous injection of degarelix acetate plus 0.075mg estradiol transdermal patch (applied twice per week)

Drug: Degarelix; Drug: Transdermal Estradiol Patch

Interventions

Degarelix DRUG

After first undergoing a pregnancy test, a clinician will administer an 80-mg subcutaneous injection of degarelix acetate (20 mg/mL; Ferring Pharmaceuticals Inc, Parsippany, NJ) to the women. A second injection will occur at 10 weeks. Compliance to the intervention will be ensured by having participants receive injections in the Clinical and Translational Research Center (CTRC), where all study visits will take place.

Also known as: GnRH antagonist, Ovarian suppression

Degarelix plus transdermal estradiol; Degarelix plus transdermal placebo

Transdermal Estradiol Patch DRUG

Treatment will be a weekly transdermal patch (0.075 mg) administered in a double-blinded manner. This estradiol dose increases serum estradiol to \~90 pg/mL. Compliance to the intervention will be monitored by having participants keep a log that tracks patch use.

Degarelix plus transdermal estradiol

Transdermal Placebo Patch DRUG

Treatment will be a weekly transdermal patch (placebo inactive) administered in a double-blinded manner. Compliance to the intervention will be monitored by having participants keep a log that tracks patch use.

Degarelix plus transdermal placebo

Eligibility Criteria

• Age: 20 Years - 45 Years
• Sex: female
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Age criteria of 20-45 years: the investigators are determining the effects of ovarian suppression on adiposity and vascular in premenopausal women;
• Premenopausal defined as normal menstrual cycle function defined as no more than 1 missed cycle in the previous year: irregular menstrual or missed menstrual cycles could indicate that women are anovulatory and/or perimenopause;
• Not pregnant or planning to become pregnant;
• Not lactating in the last 3 months;
• Serum FSH \<10 IU/L measured during days 1-10 of the menstrual cycle: to ensure the woman is premenopausal and not perimenopausal;
• Not on hormonal contraception in the last 3 months;
• Sedentary or recreationally active (\<2 days/wk vigorous exercise);
• No use of medications that might influence vascular function (i.e., antihypertensives, lipid lowering medications, blood thinners);
• No use of antioxidant supplements or chronic NSAIDs or be willing to go off them for 4 weeks prior to enrollment in the study;

You may not qualify if:

• Diabetic or fasted glucose \>126 mg/dL;
• Body mass index (BMI) \>35 kg/m2;
• Weight change \>5 kg in the last 3 months;
• Use of glucocorticoids (inhaled, oral, topical) or drugs that affect glucocorticoid metabolism (e.g., ketoconazole) in the last 3 months;
• Excess alcohol consumption, defined as \>14 drinks per week by self-report;
• Known hypersensitivity to study medications;
• Depressive symptoms, defined as a CES-D score \>16;
• Resting blood pressure \>150/90 mmHg;
• Preexisting or active cardiac, renal, or hepatic disease: past or current history of these diseases or conditions;
• Active or chronic infection: inflammation associated with active or chronic infections impair vascular function;
• Thyroid dysfunction, defined as an ultrasensitive TSH \<0.5 or \>5.0 mU/L; volunteers with abnormal TSH values will be reconsidered for participation in the study after follow-up evaluation by the PCP with initiation or adjustment of thyroid hormone replacement;
• Smoking or Tobacco use within the previous 12 months;
• Severe low bone mass or osteoporosis, defined as a hip or lumbar spine T-score \<-2.0: safety reasons, women who are randomized to the ovarian suppression plus placebo group could see a decrease in bone mineral density due to the suppression of estrogen;
• History of venous thromboembolic event (VTE): safety reasons, estradiol therapy can increase the risk of VTE;
• History of breast cancer or other estrogen-dependent neoplasm: estradiol therapy is contraindicated;

Sponsors & Collaborators

• University of Colorado, Denver: lead
• National Institute on Aging (NIA): collaborator

Study Sites (1)

University of Colorado Anschutz Medical Campus

Aurora, Colorado, 80045, United States

RECRUITING

MeSH Terms

Conditions

Obesity

Interventions

acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide; LHRH, Ac-Nal(1)-Cpa(2)-Trp(3)-Arg(6)-Ala(10)-

Condition Hierarchy (Ancestors)

Overweight; Overnutrition; Nutrition Disorders; Nutritional and Metabolic Diseases; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Officials

• Kerrie Moreau, PhD

  University of Colorado Denver Anschutz Medical Campus

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Kerrie Moreau, PhD

CONTACT

303-724-1914; kerrie.moreau@cuanschutz.edu

Claire Cox, BA

CONTACT

303-724-1396; claire.cox@cuanschutz.edu

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: BASIC SCIENCE
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 7, 2024
• First Posted: February 20, 2024
• Study Start: June 1, 2024
• Primary Completion (Estimated): May 31, 2028
• Study Completion (Estimated): August 31, 2028
• Last Updated: June 20, 2024

Record last verified: 2024-06

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)